Category Archives: Human Longevity

LEEDS, England--(BUSINESS WIRE)-- 4D Pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces the appointment of John Beck as Chief Financial Officer (CFO) and member of the Companys management team, bringing over 30 years of experience in finance, including three previous positions as Chief Financial Officer of publicly traded life sciences companies.

John will be an important addition to 4D pharmas management team at such a pivotal time, as the company prepares to close our SPAC merger and begin trading on NASDAQ. His deep experience and financial expertise as a CFO of several publicly traded life sciences companies will be critical as we further grow our company and global footprint, said Duncan Peyton, Chief Executive Officer of 4D pharma.

John Beck brings over 30 years of experience in financial and biopharmaceutical industry management experience. This includes three previous positions as Chief Financial Officer of publicly traded life sciences companies where he has achieved considerable results in areas including finance, business and corporate development, strategy, and commercialization.

I look forward to contributing the success of 4D pharma at this exciting stage in its development. 4Ds pioneering work to develop promising therapies across a number of disease areas from oncology to the gut-brain axis is clearly differentiated through its MicroRx platform and LBP product candidates, said John Beck, Chief Financial Officer of 4D pharma. With several key data readouts upcoming and our potential listing on NASDAQ, I believe 4D is well positioned to expand and enhance its investor base and drive further shareholder value for the remainder of 2021.

Mr. Beck has extensive investor and public relations, corporate governance, regulatory, and fundraising expertise. Most recently he was the Senior Vice President, Finance and CFO of Ritter Pharmaceuticals from May 2018 to May 2020, where he oversaw its successful merger with Qualigen Therapeutics, Inc. Prior to that, Mr. Beck served as Executive Manager and CEO at Wellspring Water Technologies, LLC and CEO of West Tech Medical, LLC from October 2015 to May 2018. Mr. Beck also was the CFO and Senior Vice President of Finance and Operations of Ardea Biosciences from February 2008 to June 2012, where he raised over $160 million in public financings, executed a $400 million out-licensing transaction with Bayer Pharmaceuticals and completed a $1.2 billion merger with AstraZeneca. Mr. Beck also held positions as Senior Vice President of Finance, Treasurer and CFO of Metabasis Therapeutics, and the Director of Finance at Neurocrine Biosciences, leading both through successful NASDAQ IPOs.

In addition, Mr. Beck currently serves on the Board of Directors of San Diego-based Artelo Biosciences, as a scientific advisor and mentor to the University of San Diegos student-run TRITON fund. Mr. Beck holds a B.A. in Accounting from the University of Washington, Seattle, a degree in theology from a Seattle area seminary and is a licensed CPA (inactive status) in the state of California.

About 4D pharma

Founded in February 2014, 4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.

4D pharma's Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has six clinical programs, namely a Phase I/II study of MRx0518 in combination with KEYTRUDA (pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumors, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma (NCT03851250), a Phase II study of MRx-4DP0004 in patients hospitalized with COVID-19 (NCT04363372), and Blautix in Irritable Bowel Syndrome (IBS) (NCT03721107) which has completed a successful Phase II trial. Preclinical-stage programs include candidates for CNS disease such as Parkinson's disease and other neurodegenerative conditions. The Company has a research collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.

In October 2020 4D pharma announced its intention to merge with Longevity Acquisition Corporation (NASDAQ: LOAC), a special purpose acquisition company (SPAC), and seek a NASDAQ listing. The merger is expected to be completed and the NASDAQ listing of 4D pharma American Depositary Shares (ADSs) under the ticker symbol 'LBPS' is currently expected to become effective in early 2021, subject to the satisfaction of closing conditions, including approval of 4D shareholders and Longevity shareholders and the approval by Nasdaq of the listing of ADSs.

For more information, refer to http://www.4dpharmaplc.com.

Forward-Looking Statements

This press release contains "forward-looking statements." All statements other than statements of historical fact contained in this announcement, including without limitation statements regarding timing of the clinical trial are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the United States Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking statements are often identified by the words "believe," "expect," "anticipate," "plan," "intend," "foresee," "should," "would," "could," "may," "estimate," "outlook" and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the Company's current expectations, beliefs and assumptions concerning future developments and business conditions and their potential effect on the Company. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates.

All of the Company's forward-looking statements involve known and unknown risks and uncertainties, some of which are significant or beyond its control, and assumptions that could cause actual results to differ materially from the Company's historical experience and its present expectations or projections. The foregoing factors and the other risks and uncertainties that affect the Company's business, including the risks of delays in the commencement of the clinical trial and those additional risks and uncertainties described the documents filed by the Company with the US Securities and Exchange Commission (SEC), should be carefully considered. The Company wishes to caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any of its forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law.

Additional Information about the Transaction and Where to Find it

This press release is being made in respect of a proposed business combination involving 4D and Longevity. Following the announcement of the proposed business combination, 4D filed a registration statement on Form F-4 (the Registration Statement) with the SEC which was declared effective on February 25, 2021. This press release does not constitute an offer to sell or the solicitation of an offer to buy or subscribe for any securities or a solicitation of any vote or approval nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The Registration Statement includes a prospectus with respect to 4Ds ordinary shares and ADSs to be issued in the proposed transaction and a proxy statement of Longevity in connection with the merger. The proxy statement/prospectus has been mailed to the Longevity shareholders on or about February 26, 2021. 4D and Longevity also plan to file other documents with the SEC regarding the proposed transaction.

This press release is not a substitute for any prospectus, proxy statement or any other document that 4D or Longevity may file with the SEC in connection with the proposed transaction. Investors and security holders are urged to read the Registration Statement and, when they become available, any other relevant documents that will be filed with the SEC carefully and in their entirety because they will contain important information about the proposed transaction.

You may obtain copies of all documents filed with the SEC regarding this transaction, free of charge, at the SECs website (www.sec.gov). In addition, investors and security holders will be able to obtain free copies of the Registration Statement and other documents filed with the SEC without charge, at the SECs website (www.sec.gov) or by calling +1-800-SEC-0330.

Participants in the Solicitation

Longevity and its directors and executive officers and other persons may be deemed to be participants in the solicitation of proxies from Longevitys shareholders with respect to the proposed transaction. Information regarding Longevitys directors and executive officers is available in its annual report on Form 10-K for the fiscal year ended February 29, 2020, filed with the SEC on April 30, 2020. Additional information regarding the participants in the proxy solicitation relating to the proposed transaction and a description of their direct and indirect interests is contained in the Registration Statement.

4D and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the shareholders of Longevity in connection with the proposed transaction. A list of the names of such directors and executive officers and information regarding their interests in the proposed transaction is included in the Registration Statement.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210301005053/en/

Original post:
4D Pharma Appoints John Beck as Chief Financial Officer and Member of the Management Team - BioSpace

Its time to stop mythologizing Black women trying to survive in a world that doesnt value them.

Content warning: police violence, Black death

Black women arent your superheroes. We arent selfless vigilantes, watching through the night for signs of trouble. Were not perched on the wings of the city, waiting to swoop in and save white people in distress.

Black women are human amazing, creative, self-sacrificing humans but human nonetheless. We save others to save ourselves.

But continual demands on Black women to act while others do nothing is killing us.

The last 12 months of nonstop political and cultural turmoil a pandemic, constant images of police brutality, contested elections, insurrection have only further proven how invaluable Black women are to society.

These recent affairs have produced countless examples of Black women turned into superhero caricatures by the white gaze; white people are obsessed with us, obsessed with what we can do for them.

Amanda Gorman, the Youth Poet Laureate who spoke at President Bidens inauguration, has been portrayed as a larger-than-life superhero, a magical being meant to save the United States from itself.

Stacey Abrams (with a coalition of other Black women) helped expand voter accessibility in Georgia. Shes being painted as an almost fanciful champion, saving marginalized votes from the evil clutches of voter suppression tactics without so much as breaking a sweat.

Black women, as a collective, helped the Democratic Party crawl to victory in the 2020 presidential election.

Dont get it twisted; these Black women are wholeheartedly brilliant full stop but white people have mythologized them.

Black women have gone from attentive citizens participating in democracy to protect their communities interests to Americas safety net. Shine the Bat-Signal and well be there in 5.

Beyond establishment politics, Black women are also at the front lines of revolutionary work, slaying systems that disproportionately execute Black people.

Black women have led the months of protests, calling for reverence toward Black life (long after supposed white allies fell to the wayside).

Were the ones creating and circulating calls to action. Were the ones making posters for protests. Were the ones giving our time and energy to various marches and rallies.

Black women do the bulk of organizing, leading, and participating in these revolutionary moments as others stand aside and contribute little beyond pledges to do better.

We save democracies. We save our people. All while juggling personal responsibilities and bearing the cross of what it means to be a Black woman in the world.

And yet, despite the deep and abundant ways that Black women serve everyone, no one shows up for us. No one thanks us for the labor we do at least not in any meaningful way.

No one cares about our constant exhaustion given the trauma and pain we carry and what it does to us physically, emotionally, and mentally.

When it comes to opportunities to show up for us and with us, people rarely find the time. Theyre lackluster about showing any solidarity or support for us; the dedication isnt reciprocated.

Historically, movements like first-wave feminism pushed out Black women in fear that our calls for humanity would weaken the overall movement. Even as Black trans women led the queer liberation movement of the 1960s and 70s, their critical involvement is routinely forgotten.

Currently, rallies for #SayHerName have notably fewer attendants. In fact, the hashtag we created to highlight our unique plight has been co-opted and misused, silencing our message.

Vigils honoring Black trans women are quietly circulated and sparsely attended.

Instead of celebrating the work Black women do and the investments we constantly make in others, the world harms us. The world hates us. The world finds new and innovative ways to humiliate, degrade, and commit violence upon us.

People especially white people who self-consciously tweet about thanking Black women use Black women as a steppingstone to continue living a life of ignorant bliss and placidity.

Despite our cultural and political climate demanding that people finally respect the fullness and beauty of Black life, people still find it in their chest to disrespect and dehumanize Black women.

The killings of Breonna Taylor, Nina Pop, and countless other Black women show how disposable we are.

The fact that the officer who killed Breonna Taylor was punished for wanton endangerment (for the bullets that hit a neighboring apartments walls) versus the bullets that sliced through Breonnas body shows how little Black women matter.

Charges were brought for endangering human life as if Breonnas life wasnt snatched without hesitation. Let this sentencing and others without a flake of justice show how Black women are regarded in this life.

Black women are the victims of all kinds of violence.

The violence looks like being categorically harassed on Twitter by all different races of men.

The violence looks like Talib Kweli dedicating hours upon hours of tweeting to harass Maya Moody, a Black woman whom he had a disagreement with.

The violence looks like Black women being disproportionately affected by and dying from domestic violence.

The violence looks like the epidemic of Black trans women being murdered.

The violence looks like Megan Thee Stallion being shot by Tory Lanez and having her fellow music industry colleagues stay silent about her abuse. It looks like people mocking her trauma, calling her a snitch, and making jokes at her expense.

These types of hate and vitriol are specifically reserved for us.

Our physical and mental health is impaired as people stand around and watch us suffer.

Black women are disproportionately affected by mental health conditions like anxiety, having more intense and chronic symptoms compared with our white counterparts.

Our physical pain is routinely downplayed and undertreated by white doctors.

Black women also have a higher risk of developing and dying from illnesses such as heart disease and cancer.

Were often told these health disparities stem from lifestyle factors, despite research that says otherwise.

Our bodies are literally being worn down by the stress we face, further proving that the lived reality of Black women isnt just a trendy political discussion point. Its an all too real public health crisis that erodes at our very being.

The way that the United States continually burdens Black women with its demands for our intelligence, our sympathy, our action, and our myriad other talents, all the while ignoring our well-being and humanity, is a problem.

Its an issue thats literally killing us. As Black women, we have a responsibility to ourselves to practice self-care and preservation. Of course, the practical ability to do this is difficult considering every crisis that plagues anyone will befall us 10 times worse.

Whenever possible, though, we need to draw boundaries and put ourselves first.

And the wave of people who shower us with empty thanks on social media while doing nothing material to protect our welfare also have a responsibility. Simply put: You all need to legitimately and unquestionably ride for us.

You need to give your money to Black women who are on the front lines. You need to give your money to Black women who move through the world, simply trying to survive.

You need to use your platform to decry the injustices Black women suffer, who die at the hands of misogynoir.

You need to listen to Black women, when we tell you we are hurting, when we tell you that you are hurting us.

You need to examine and unlearn your assumptions about what Black women do and do not owe you (spoiler alert: we owe you nothing).

You need to stop treating us like your emergency brake, as if were only placed on this earth to serve.

Black women deserve to experience the fullness of life without being run ragged by the demands of others.

We should be able to live with some dignity without fearing violence or a premature death because of what the world does to us.

Everyone absolutely everyone has a part to play in ensuring that Black women are protected and showing us that we matter.

Gloria Oladipo is a Black woman and freelance writer, musing about all things race, mental health, gender, art, and other topics. You can read more of her funny thoughts and serious opinions on Twitter.

More here:
As Black Women, We Need to Save Ourselves, Not the World - Healthline

The Action Plan of the European Pillar of Social Rights could lead to a profound shift in the enjoyment of human rights in the EU.

The pandemic and the measures taken to combat it have upended many lives. For millions around the world, Covid-19 has brought protracted uncertainty, isolation and hardship, with no end in sight.

The global poverty rate is likely to increase for the first time in 20 years, risking the reversal of substantial gains. The United Nations secretary-general, Antnio Guterres, has called for a global reset as the world continues to reel from the pandemic, which has claimed more than two million lives and some 500 million jobs.

In Europe, the detrimental impact on the right to physical and mental health has been compounded by over-reliance on the institutional care of older persons and persons with disabilities. And those already in a precarious situation have been hit hardest, with women and minorities particularly afflicted.

At the beginning of last week, the Council of the EU adopted conclusions on a human-rights-based post-Covid-19 recovery, restating the indivisibility of all human rights and reaffirming that a socio-economic response with human rights at its core would enable a more sustainable recovery and make systems more resilient to future shocks. A week earlier, in a joint communication on multilateralism from the European Commission and the high representative for foreign affairs and security policy, the EUs commitment to human rights was presented not only as a matter of values but as an essential component of its support for a rules-based international order.

But the commitment must start at homewith a human-rights-based approach to the Action Plan, due tomorrow, to implement the European Pillar of Social Rights agreed in 2017.

"Social Europe publishes thought-provoking articles on the big political and economic issues of our time analysed from a European viewpoint. Indispensable reading!"

Columnist for The Guardian

Thank you very much for your interest! Now please check your email to confirm your subscription.

Expectations are high for the Action Planfor improving working conditions, tackling homelessness and enhancing social protection. Rightly so, because the pandemic has created an unprecedented opportunity for the EU to trigger a seismic shift in the enjoyment of social rights in the union.

An approach that places human beings and their rights at its centrenot as passive recipients of services but as rights-holders with agencyis the only route to a sustainable recovery. The plan should be guided by international human-rights treaties and recommendations, as well as the UNs 2030 Agenda for Sustainable Development.

While states, as primary duty-bearers under international law, carry the main responsibility to respect, protect and fulfil social rights, the role of the EU institutions cannot be overstated. A rights-based approach will not only help close protection gaps for people living in Europe; it will also strengthen coherence among international, regional and national systems and enhance legal certainty for member states and domestic courts.

But this is about more than compliance: international human rights can sharpen the effectiveness of policy interventions. In addition to the EUs own tools, such as the Social Scoreboard, the findings of UN treaty bodies establish a useful baseline as to where countries stand in terms of social rights. As parties to the UN Convention on Economic, Social and Cultural Rights, member states are, after all, bound to implement these norms. In this vein, the Action Plan should also explicitly recognise adequate housing and social protection as matters of human rightsnot as a commodity or as services.

As you may know, Social Europe is an independent publisher. We aren't backed by a large publishing house or big advertising partners. For the longevity of Social Europe we depend on our loyal readers - we depend on you. You can support us by becoming a Social Europe member for less than 5 Euro per month.

Thank you very much for your support!

It is precisely at this time of crisis that solid public participation is needed. Rights-holders should be enabled to participate effectively in the implementation and review of the social pillarespecially representatives of the most marginalised. To collect reliable information on who they are, the Action Plan should call on states to collect data on socio-economic status, disaggregated by age, sex, race/ethnicity, national origin, disability, education and property.

Because of their proximity to the citizen, local and regional authorities should be more involved in formulating policy. Their views on what works and what doesnt, in healthcare, housing or employment, including job creation, are critical to designing and implementing policies that work for all.

Clear quantitative and qualitative targets should be set and accompanied by a robust system to measure results. Indicators already exist to track and assess progresson human rights from the UN Human Rights Office plus those associated with the Sustainable Development Goals. The Action Plan should also envisage transparent and publicly accessible tools to track linked financial allocations and expenditures.

The EU and its member states have been the strongest supporters of national human-rights institutions around the world and should systematically bring them on board in the Action Plan. National human-rights institutions are state-mandated bodies, independent of government, which advise on legislation, monitor human-rights compliance, raise public awareness and help individuals claim their rights. They also act as a bridge to the international human-rights system.

By aligning its internal policies with its vision for external action, as also articulated in the EU Action Plan for Human Rights and Democracy, Europe can lead by example. But internal coherence will also be central to the plans success. Hence, the importance of joined-up implementation with various other EU policies seeking to advance economic and social rights: the Disability Strategy, the Anti-Racism Action Plan, the Gender Equality Strategy, the Child Guarantee, the Youth Guarantee, the Strategic Framework on Roma Equality and Inclusion, and the LGBTI+ Equality Strategy.

We have before us a chance to close serious gaps in the enjoyment of social rights across the region. If this opportunity is seized, it will lead to better and tangible outcomes in the Covid-19 recovery andmost importantlywill guarantee a life of greater dignity for all.

Go here to see the original:
Aligning the social pillar with human rights - Social Europe

Feb. 26, 2021 07:00 UTC

LEEDS, England--(BUSINESS WIRE)-- 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces that the United States Securities and Exchange Commission (SEC) has declared effective its registration statements on Form F-4 with respect to the issuance of 4D pharma American Depositary Shares (ADSs) to the shareholders of Longevity Acquisition Corporation (NASDAQ: LOAC) (Longevity), a NASDAQ-listed special purpose acquisition company (SPAC), in connection with the previously announced merger between 4D pharma and Longevity.

It is expected that 4D pharma ADSs will begin trading on NASDAQ under the ticker symbol LBPS following completion of the merger, subject to the satisfaction of the conditions to closing in the merger agreement between 4D pharma and Longevity, including approvals of 4D pharma and Longevity shareholders.

As reported in October 2020, the registration statement facilitates the creation of a trading market in the US for ADSs representing the Company's Ordinary Shares. 4D pharmas Ordinary Shares will continue to be admitted to trading on AIM, a market operated by the London Stock Exchange, under the current ticker symbol DDDD.

The Company will send a circular to 4D pharma shareholders in due course in order to convene a General Meeting to, inter alia, approve the merger.

About 4D pharma

Founded in February 2014, 4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.

4D pharma's Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has six clinical programmes, namely a Phase I/II study of MRx0518 in combination with KEYTRUDA (pembrolizumab) in solid tumours, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumours, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma, a Phase II study of MRx-4DP0004 in patients hospitalised with COVID-19, and Blautix in Irritable Bowel Syndrome (IBS) which has completed a successful Phase II trial. Preclinical-stage programmes include candidates for CNS disease such as Parkinson's disease and other neurodegenerative conditions. The Company has a research collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.

In October 2020 4D pharma announced its intention to merge with Longevity Acquisition Corporation (NASDAQ: LOAC), a special purpose acquisition company (SPAC), and seek a NASDAQ listing. The merger is expected to be completed and the NASDAQ listing of 4D pharma American Depositary Shares (ADSs) under the ticker symbol LBPS is currently expected to become effective in early 2021, subject to approval of 4D Shareholders and Longevity Shareholders.

For more information, refer to https://www.4dpharmaplc.com

Forward-Looking Statements

This press release contains "forward-looking statements." All statements other than statements of historical fact contained in this announcement, including without limitation statements regarding expected trading of 4D pharma ADSs on NASDAQ and the potential timing thereof, are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the United States Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking statements are often identified by the words "believe," "expect," "anticipate," "plan," "intend," "foresee," "should," "would," "could," "may," "estimate," "outlook" and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the Company's current expectations, beliefs and assumptions concerning future developments and business conditions and their potential effect on the Company. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates.

All of the Company's forward-looking statements involve known and unknown risks and uncertainties, some of which are significant or beyond its control, and assumptions that could cause actual results to differ materially from the Company's historical experience and its present expectations or projections. The foregoing factors and the other risks and uncertainties that affect the Company's business, including the risks of delays in admitting the ADSs to trading on NASDAQ and those additional risks and uncertainties described the documents filed by the Company with the US Securities and Exchange Commission (SEC), should be carefully considered. The Company wishes to caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any of its forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law.

Additional Information about the Transaction and Where to Find it

This press release is being made in respect of a proposed business combination involving 4D and Longevity. Following the announcement of the proposed business combination, 4D filed a registration statement on Form F-4 (the Registration Statement) with the SEC, which Registration Statement has been declared effective by the SEC. This press release does not constitute an offer to sell or the solicitation of an offer to buy or subscribe for any securities or a solicitation of any vote or approval nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The Registration Statement includes a preliminary prospectus with respect to 4Ds ordinary shares and ADSs to be issued in the proposed transaction and a proxy statement of Longevity in connection with the merger. The proxy statement/prospectus will be provided to the Longevity shareholders. 4D and Longevity also plan to file other documents with the SEC regarding the proposed transaction.

This press release is not a substitute for any prospectus, proxy statement or any other document that 4D or Longevity may file with the SEC in connection with the proposed transaction. Investors and security holders are urged to read the Registration Statement and, when they become available, any other relevant documents that will be filed with the SEC carefully and in their entirety because they will contain important information about the proposed transaction.

You may obtain copies of all documents filed with the SEC regarding this transaction, free of charge, at the SECs website (www.sec.gov). In addition, investors and security holders will be able to obtain free copies of the Registration Statement and other documents filed with the SEC without charge, at the SECs website (www.sec.gov) or by calling +1-800-SEC-0330.

Participants in the Solicitation

Longevity and its directors and executive officers and other persons may be deemed to be participants in the solicitation of proxies from Longevitys shareholders with respect to the proposed transaction. Information regarding Longevitys directors and executive officers is available in its annual report on Form 10-K for the fiscal year ended February 29, 2020, filed with the SEC on April 30, 2020. Additional information regarding the participants in the proxy solicitation relating to the proposed transaction and a description of their direct and indirect interests is contained in the Registration Statement.

4D and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the shareholders of Longevity in connection with the proposed transaction. A list of the names of such directors and executive officers and information regarding their interests in the proposed transaction is included in the Registration Statement.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210225005885/en/

More here:
4D Pharma Announces US SEC Declares Registration Statement Effective with Respect to the Issuance of 4D Pharma American Depositary Shares on NASDAQ -...

ALAMEDA, Calif. & PITTSBURGH--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (AgeX; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and cell regeneration, and LyGenesis, Inc. (LyGenesis), a privately held biotechnology company developing cell therapies that enable organ regeneration, announced today that they will proceed to negotiate an agreement for a merger of the two companies. LyGenesis recently received U.S. Food and Drug Administration clearance for its Investigational New Drug application to conduct a Phase 2a clinical trial on the safety, tolerability, and efficacy of its lead cell therapy for patients with end-stage liver disease, with study initiation planned for 2021. The combined companys pipeline would also include thymus, pancreas, and kidney regeneration, in addition to the existing AgeX assets, including UniverCyte, which uses the HLA-G gene to potentially confer low immune observability to cells to suppress rejection of transplanted cells.

About the Proposed Merger

Based on the terms currently being discussed, a newly formed subsidiary of AgeX would merge into LyGenesis. At the closing of the merger, AgeX would issue to LyGenesis stockholders a number of shares of AgeX common stock representing two-thirds of the total number of shares of AgeX common stock to be outstanding immediately following the consummation of the merger on a fully diluted basis, but prior to the issuance of additional shares in a contemplated capital raising transaction following the execution of a merger agreement and contingent on the closing of the merger. Dr. Michael Hufford, who is the current Chief Executive Officer (CEO) of LyGenesis, upon successful merger would become CEO of the entity that survives the transaction (which includes both AgeX and LyGenesis). Under the terms being discussed, if the merger is completed, AgeXs pre-merger stockholders would receive an 80% economic interest in AgeXs induced tissue regeneration or iTR technology; the terms and structure of such economic interest have not yet been determined.

There can be no assurance that the negotiations between AgeX and LyGenesis will result in the execution of a definitive merger agreement on the terms being discussed or at all, or, if a merger agreement is entered into, that the merger will be consummated. The completion of any merger would be subject to approval by a special independent committee of the AgeX Board of Directors and by the respective Boards of Directors of both companies. The merger would also be subject to approval by AgeX stockholders and LyGenesis stockholders, including in each case approval by both a majority of the outstanding shares and by the holders of a majority of the shares not held by Juvenescence Limited.

Juvenescence Limited (Juvenescence) is the largest shareholder of each of AgeX and LyGenesis. Juvenescence beneficially owns approximately 52.7% of the AgeX common stock determined as disclosed in its most recent amendment to its Schedule 13D filed with the Securities and Exchange Commission, and owns approximately 48% of the common stock of LyGenesis (assuming the conversion of its convertible debt into equity). The Chairman of AgeXs Board of Directors, Dr. Gregory Bailey, is the Chief Executive Officer of Juvenescence. Two directors of LyGenesis, James Mellon and David Ellam, are the Chairman and the Chief Financial Officer of Juvenescence, respectively.

This communication is not an offer to sell any securities or a solicitation of any vote or approval and AgeX is not offering to sell, or soliciting an offer to buy, any securities in any state where the offer or sale is not permitted.

This communication is for informational purposes only and does not constitute an offer to sell any shares of AgeX common stock or a solicitation of any vote or approval, nor is it a substitute for a prospectus that may be included in a registration statement that may be filed by AgeX with the Securities and Exchange Commission (the SEC) under the Securities Act of 1933, as amended, with respect to the potential merger transaction, or a proxy statement that may be provided to AgeX stockholders. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ ANY PROSPECTUS OR PROXY STATEMENT FOR THE MERGER TRANSACTION AND ALL OTHER RELEVANT DOCUMENTS THAT AGEX MAY FILE WITH THE SEC, IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. All documents referred to above, if and when filed by AgeX, will be available free of charge at the SECs website (www.sec.gov) or by directing a request to AgeXs Chief Financial Officer at 1101 Marina Village Parkway, Suite 201, Alameda, California 94501 or apark@agexinc.com.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly-defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AgeX is developing its core product pipeline for use in the clinic to extend human healthspan and is seeking opportunities to establish licensing and collaboration agreements around its broad IP estate and proprietary technology platforms.

For more information, please visit http://www.agexinc.com or connect with the company on Twitter, Facebook, and YouTube.

About LyGenesis, Inc

LyGenesis is a biotechnology company whose cell therapies enable organ regeneration by using a patients lymph nodes as bioreactors to regrow functioning ectopic organs. LyGenesiss cell therapies are engrafted using endoscopic ultrasound procedure, which is associated with decreased medical risks and costs relative to full organ transplantation. LyGenesiss lead allogeneic cell therapy program is focused on liver regeneration for patients with end stage liver disease. Its drug development pipeline includes positive preclinical data for thymus, pancreas, and kidney regeneration. Privately held, LyGenesis is headquartered in Pittsburgh, Pennsylvania. To learn more, please visit lygenesis.com.

Forward-Looking Statements

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries particularly those mentioned in the cautionary statements found in more detail in the Risk Factors section of AgeXs Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (copies of which may be obtained at http://www.sec.gov). Further, the potential merger with LyGenesis is subject to additional risks and uncertainties, including (i) negotiation of a definitive merger agreement, (ii) approval of a merger agreement by the respective boards of directors of AgeX and LyGenesis, (iii) approval of the merger agreement by AgeX stockholders, (iv) the satisfaction or waiver of such contractual conditions to the merger as may be included in the merger agreement, (v) the ability of AgeX and LyGenesis to raise additional capital for the merged company, (vi) potential difficulties integrating the business practices and operations of AgeX with the business practices and operations of LyGenesis; including potential difficulties in conforming accounting policies, procedures, internal controls, and financial records of LyGenesis with AgeX, (vii) the uncertain expense and outcome of the planned clinical trial of LyGenesis liver failure treatment, (viii) the cost and risks associated with the development of additional cell therapies in the LyGenesis product pipeline, (ix) unexpected expenditures or assumed liabilities that may be incurred as a result of the merger, (x) inability to accurately forecast the performance of LyGenesis and AgeX as an integrated company, and (xii) expected synergies between LyGenesis and AgeX may be materially different from actual results. Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

Follow this link:
AgeX Therapeutics and LyGenesis to Negotiate Merger Agreement - Business Wire

The gut microbiome is an integral component of the body, but its importance in the human aging process is unclear. ISB researchers and their collaborators have identified distinct signatures in the gut microbiome that are associated with either healthy or unhealthy aging trajectories, which in turn predict survival in a population of older individuals. The work was just published in the journal Nature Metabolism.

The research team analyzed gut microbiome, phenotypic and clinical data from over 9,000 people between the ages of 18 and 101 years old across three independent cohorts. The team focused, in particular, on longitudinal data from a cohort of over 900 community-dwelling older individuals (78-98 years old), allowing them to track health and survival outcomes.

The data showed that gut microbiomes became increasingly unique (i.e. increasingly divergent from others) as individuals aged, starting in mid-to-late adulthood, which corresponded with a steady decline in the abundance of core bacterial genera (e.g. Bacteroides) that tend to be shared across humans.

Strikingly, while microbiomes became increasingly unique to each individual in healthy aging, the metabolic functions the microbiomes were carrying out shared common traits. This gut uniqueness signature was highly correlated with several microbially-derived metabolites in blood plasma, including one tryptophan-derived indole that has previously been shown to extend lifespan in mice. Blood levels of another metabolite phenylacetylglutamine showed the strongest association with uniqueness, and prior work has shown that this metabolite is indeed highly elevated in the blood of centenarians.

This uniqueness signature can predict patient survival in the latest decades of life, said ISB Research Scientist Dr. Tomasz Wilmanski, who led the study. Healthy individuals around 80 years of age showed continued microbial drift toward a unique compositional state, but this drift was absent in less healthy individuals.

Interestingly, this uniqueness pattern appears to start in mid-life 40-50 years old and is associated with a clear blood metabolomic signature, suggesting that these microbiome changes may not simply be diagnostic of healthy aging, but that they may also contribute directly to health as we age, Wilmanski said. For example, indoles are known to reduce inflammation in the gut, and chronic inflammation is thought to be a major driver in the progression of aging-related morbidities.

Prior results in microbiome-aging research appear inconsistent, with some reports showing a decline in core gut genera in centenarian populations, while others show relative stability of the microbiome up until the onset of aging-related declines in health, said microbiome specialist Dr. Sean Gibbons, co-corresponding author of the paper. Our work, which is the first to incorporate a detailed analysis of health and survival, may resolve these inconsistencies. Specifically, we show two distinct aging trajectories: 1) a decline in core microbes and an accompanying rise in uniqueness in healthier individuals, consistent with prior results in community-dwelling centenarians, and 2) the maintenance of core microbes in less healthy individuals.

This analysis highlights the fact that the adult gut microbiome continues to develop with advanced age in healthy individuals, but not in unhealthy ones, and that microbiome compositions associated with health in early-to-mid adulthood may not be compatible with health in late adulthood.

This is exciting work that we think will have major clinical implications for monitoring and modifying gut microbiome health throughout a persons life, said ISB Professor Dr. Nathan Price, co-corresponding author of the paper.

This research project was conducted by ISB and collaborators from Oregon Health and Science University, University of California San Diego, University of Pittsburgh, University of California Davis, Lifestyle Medicine Institute, and University of Washington. It was supported in part by a Catalyst Award in Healthy Longevity from the National Academy of Medicine, and the Longevity Consortium of the National Institute on Aging.

ReferenceWilmanski T, Diener C, Rappaport N, et al. Gut microbiome pattern reflects healthy ageing and predicts survival in humans. Nature Metabolism. Published online 2021. doi:10.1038/s42255-021-00348-0

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Excerpt from:
Healthy Aging and Longevity Linked to Gut Microbiome - Technology Networks

Life expectancy is largely governed by how effectively we can wield the tools at our disposal. What we choose to put in our body illustrates this point - poor dietary decisions can invite a host of health problems, whereas eating well can provide a barrier against them. Supplements are often met with a healthy dose of scepticism, but evidence suggests that some can extend your lifespan.

One study of over 41,000 metformin users found the drug decreased frailty by 24 percent, decreased cancer risk by six percent, reduced cardiovascular disease risk by 19 percent, and increased overall lifespan by six percent.

In their concluding remarks, the study researchers wrote: The apparent reductions in all-cause mortality and diseases of ageing associated with metformin use suggest that metformin could be extending life and health spans by acting as a neuroprotective agent.

According to Dartnell, another supplement that may extend ones lifespan is NMN (nicotinamide mononucleotide).

As he explained Inside the body, NMN is transformed into NAD+ - a critical coenzyme found in every cell in your body.

DON'T MISSHow to live longer: Eat a 'modified' Mediterranean diet[TIPS]Statins side effecs: Three side effects in your eyes[ADVICE]Simon Gregson health: Coronation Street star's anxiety[INSIGHT]

The body naturally produces NAD+ but levels decline as we get older.

A key study of NAD-boosting molecules (NMN) found that boosting NAD+ levels in older age can promote health and extend lifespan.

"NMN is thought to boost our longevity genes in a way that mimics the effects of exercise," Dartnell reports.

In their concluding remarks, the study authors wrote: Restoration of NAD+ levels in old or diseased animals can promote health and extend lifespan, prompting a search for safe and efficacious NAD-boosting molecules.

"The good news is, resveratrol is also available in red wine, just in case you dont fancy taking the supplements."

According to research, determining the mechanism(s) by which resveratrol and similar molecules act, and developing methods to improve bioavailability and/or specificity, has enormous potential to benefit human health.

It is thought that resveratrol mimics fasting, said Dartnell.

As he explained, fasting is essential for switching on our longevity genes.

It should be noted that GBS Clinic does not sell any of these supplements and does not necessarily endorse or agree with the findings here. Dartnell just reporting on what the scientific literature has discovered.

See original here:
How to live longer: Three supplements linked to a longer lifespan - what to take - Express

CHICAGO, Feb. 24, 2021 /PRNewswire/ -- Picoma, a division of Zekelman Industries, is celebrating 75 years as a domestic manufacturer of electrical elbows, couplings and nipples (EC&N). Picoma has a long history in the steel industry, dating back to its founding in 1946. Company leadership and employees credit Picoma's longevity in the business to the company's commitment to domestic manufacturing.

"We started out manufacturing in Ohio 75 years ago, and we're still doing it here today," said Steve Camilletti, Picoma's general manager for North America. "The commitment to controlling our own destiny, controlling our service, controlling our quality, and to making an American-made product that's what's really kept us going all these years."

When asked about the company's future, Picoma's leadership says they've made modernization a priority. They're embracing a human-machine co-manufacturing environment that has allowed them to automate without losing their workforce. Picoma is also investing significantly in high-tech equipment, eco-friendly manufacturing practices, and online ordering and inventory management services.

Over the last five years, Picoma has added 35 U.S. jobs and continues to produce 100% American-made EC&N using domestically sourced steel.

Picoma's 75th anniversary comes on the heels of Zekelman Industries' recent "Life Reinforced" campaign launch, which aims to communicate the importance of domestic manufacturing and calls for companies to "make it here."

"When we invest in domestic manufacturing, we invest in local workers and local communities, creating opportunities for generations to come," Zekelman Industries CEO Barry Zekelman said. "Picoma is a part of our family and plays a vital role in our vision for the future. We are proud to help them celebrate 75 years in domestic manufacturing."

About PicomaPicoma, a division of Zekelman Industries, manufactures a complete line of electrical conduit fittings galvanized elbows, couplings and nipples and a complete EC&N package of aluminum, running thread and service meter masts.

About Zekelman Industries Zekelman Industries includes the operating divisions of Atlas Tube, Picoma, Sharon Tube, Wheatland Tube, Western Tube and Z Modular. It is the largest independent manufacturer of hollow structural sections (HSS) and steel pipe, and the top producer of electrical conduit and elbows, couplings and nipples in North America. Zekelman Industries delivers a broad range of pipe and tube solutions that build its customers' success.

SOURCE Zekelman Industries

Read more here:
Picoma celebrates its 75th anniversary and its place in domestic manufacturing - PRNewswire

Focus on value

After environmental shifts and business model speciation, my third fundamental prediction was about how those business models would group into genera.

Evolutionary theory implied an extreme polarisation of the three ways to create value via either technological innovation, operational efficiency or customer intimacy and hence the emergence of three distinct kinds of business.

The ancestors of these business model genera could already be seen in, for example, Roche, Mylan and Fresenius but in each case we have seen increasing specialisation and, consequently, differentiation. Increasingly, we dont have one industry, we have three.

And just as biological species succeed by uncompromising specialisation, life sciences companies that try to straddle these three genera fail.

We have seen this in the relative demise of Teva, whose leadership thought it could be both innovative and low-cost. Evolution forces choices and despises compromises.

Customer-centric, but for which customer?

As well as predicting speciation by how value is created, Generalised Darwinism also predicted speciation according to the customer for whom that value is created.

Historically, our industrys customer has been institutional healthcare systems and the governments that fund them. But as the healthcare possibilities outstrip the ability of governments to fund them, evolution predicts a habitat in which the patient pays even for advanced, expensive treatments.

And this has come to pass. Whether as co-pays, health- tourism or crowd-funding, were seeing the emergence of a market in which the patient, or his or her family, influences the choice of drugs or devices.At the extremes, we see this in Human Longevity Inc, whose model is unlikely ever to appeal to governments or insurers.

Together with the above-mentioned specialisation by how to create value, specialisation by who to create value for has created a market environment of nine habitats, each driving the evolution of different kinds of business models in the same way that desert, jungle and tundra lead to the emergence of habitat-specific species.

Equally, every failed market access submission is evidence of a business model that has tried to straddle habitats and failed (see Figure 1). In another parallel with biological species, business models reflect the habitat in which they live.

Darwins tangled bank

As I drilled deeper into the complexity of our industry, I could see that even nine business models werent enough to fully describe reality.

Even within each habitat, business models were specialising within specialisation. Technological innovators were choosing to focus on one area of science or to become science integrators for instance, with drugs and companion diagnostics.

Business models that aimed to compete on customer intimacy were polarising between small audiences so called health concierges and mass markets, which is Fitbits emerging model.

Those models that aim to imitate innovators were diverging between those who followed close behind such as biosimilars and those who chose to focus on old science the unbranded generics, for example.

To anyone who has read Darwins Origin of Species, the parallels between this complexity and his description of the tangled bank of an English hedgerow are obvious. If it is possible to improve survivability by specialising, nature will find a way to do so. Equally, if ROI can be improved by speciation, new life sciences business models will emerge.

The result is the complexity we see in our market today and is reflected in Figure 1, which identifies no less than 26 distinct business models. You can read more about this in my June 2016 PME article, Explosive Evolution.

QED

Although built on years of research, the conclusions of my research could only be putative. Evolutionary science isnt like Newtonian physics, in which the future can be perfectly extrapolated from the past.

Nor is it resolvable into simple laws like the physical sciences. It took me 120,000 words to explain my findings in my 2017 book Darwins Medicine. The only way to test my Darwinian predictions was to sit back and watch, which is what Ive done since 2016 and you may have read in my regular PME column named after the book.

By and large, I feel pretty vindicated. The six great shifts I saw emerging in 2016 have each grown into market-shaping fundamentals. The market polarisation into nine habitats has become clear and it is increasingly true to think of the industry as a family of industries.

Within each of these families, business model speciation is evident as they struggle to create value in a changing market environment. Scientists, however, are always interested in the null hypothesis. It is interesting that, for example, firms and their customers have struggled to adopt value-based pricing.

Equally, large firms have been slow to adapt both to new technologies and changing customer needs and have resorted to acquisition over organic evolution.

Both of these phenomena are examples of how evolution is slowed when it involves co-evolution between different species. These peculiarities continue to drive my research without calling into doubt the previous findings of my work.

Marxs dictum

Darwins Medicine was an attempt to explain the world of the life sciences industry. But Im reminded of the words carved on Karl Marxs tomb: The philosophers have only interpreted the world. The point, however, is to change it. Here, I think my research has had a more mixed result.

Ive worked with many companies to apply the findings of Darwins Medicine to the practicalities of their business challenges. The common thread in this work has been that firms can accelerate and direct their own evolution by the equivalent of genetic engineering.

By selectively removing, adding and changing organisational routines those little internal processes that make things happen in a company they can adapt themselves to the changes in the market that would, without adaptation, lead to their extinction.

With some companies, this concept of engineering the Routineome has been seized on with enthusiasm and executed with alacrity. I have been thrilled to see how my theory has been applied in practice to achieve both commercial ends and, necessarily, patient benefits.

With other companies, however, I have led the proverbial horse to the Darwinian water but I have not been able to make them drink.

Sometimes, firms who see the life sciences as central to their success see management sciences as irrelevant to their future. This failure to adapt cant be explained by the individual intelligence of their leaders.

I have not yet met a CEO who isnt very clever. But I think it can be explained by something that might be described as their organisational absorptive capacity. That some firms absorb new ideas better than others is a fact as established as any in management science.

It is a major explanation of why some firms last and others dont. Ultimately, this difference between firms and its consequence was, like much else, foreseen by Darwin himself. As he was paraphrased by Leon Megginson, it is those who are most responsive to change that survive.

A set of all four of the 2016 PME articles describing this work is available from the author at brian.smith@pragmedic.com

See original here:
Back to the future - PMLiVE

Ageing is deterioration of the physiological functions in human body, which is associated with several diseases, such as cardiovascular disease, neurological disease, cancer, and other metabolic disorders. It has been reported that oxidative stress and inflammation mainly contribute to the progression of ageing. This is where foods come in which can either help or hinder this process. Studies and experts advise including more ginger and garlic into your meals to help boost longevity.

In a study published in Sift Deck Research Page, the role of garlic and ginger in anti-oxidative and anti-inflammatory effects in ageing was further investigated.

The study noted: Previous studies show that garlic lowers blood pressure, cholesterol, triglycerides, and homocysteine, boost immunity and decreases oxidative stress and inflammation, which are associated with anti-ageing mechanism.

Scientific evidence suggests that garlic and ginger both showed the protective effects against oxidative stress by depleting ROS and inflammation and extending life span.

Garlic and ginger are reported to have many bioactive compounds that exert antioxidant and anti-inflammatory effects.

READ MORE:Vaccine side effects may be more severe if you've previously been infected with Covid

There have been reports of evidence which indicate the health benefits such as anti-ageing and antioxidant effects of garlic.Garlic has been shown to prevent chronic diseases such as ageing, cardiovascular diseases, cancer, and Alzheimers disease.

Garlic has been shown to prevent chronic diseases such as aging, cardiovascular diseases, cancer, and Alzheimers disease.

Moreover, garlic has been demonstrated for lowering cholesterol, triglycerides, and homocysteine, and decreasing oxidative stress and inflammation.

In addition, garlic treatment was reported to lower blood pressure, boost immunity, increase internal antioxidant like glutathione, and ameliorate fatigue.

Health experts suggest that a garlic rich diet and its supplement in any form provides regular health benefits and help to prevent serious diseases and ageing.

DON'T MISSHow to live longer: Eat a 'modified' Mediterranean diet[TIPS]Statins side effecs: Three side effects in your eyes[ADVICE]Simon Gregson health: Coronation Street star's anxiety[INSIGHT]

Gut health also plays a pivotal role in keeping health threats at bay and boosting life expectancy and new research highlights a particular herb for its gut health benefits.

According to findings presented at a research event on ageing well hosted by Yakult in Tokyo, Japan, the popular herb was shown to boost gut health and subsequently extent longevity.

The findings attribute the gut health benefits to the high amounts of natural fibres that are found in garlic, which boosts good bacteria.

These crowd out harmful gut bacteria which are known to contribute to everything from cancer and dementia to obesity and mental illness.

Ginger root is the most commonly used for home remedies like headache, nausea, common cold and emesis.

It possesses various life activities, such as antioxidant, anti-microbial, anti-inflammatory, anti-cancer activities.

There is some evidence to suggest that ginger can also inhibit and regulate several diseases, such as neurodegenerative diseases, heart diseases and metabolic disorders like diabetes mellitus and obesity, and respiratory disorders.

In a study published in the US National Library of Medicine National Institutes of Health, the effect of ginger on the lipid levels was investigated.

The study noted: Forty-five patients in the treatment group and 40 patients in the placebo group participated in this study".

There was a significant reduction in triglyceride, cholesterol, low-density lipoprotein (LDL), very low-density lipoprotein, levels of before and after study separately in each group," it continued.

Mean changes in triglyceride and cholesterol levels of the ginger group were significantly higher than the placebo group.

Mean reduction in LDL level and increase in high density lipoprotein level of ginger group were higher than the placebo group, but in VLDL level of placebo was higher than ginger."

Excerpt from:
How to live longer: Garlic and ginger can reduce cancer risk to boost longevity - Express